
    
      This is a phase Ⅱ, single-center, randomized, double-blind, placebo-controlled study, to
      evaluate the immunogenicity and safety of the recombinant COVID-19 vaccine (Sf9 cells) in the
      subjects from healthy adults and elderly adults aged 18 years and above (aged 18-60 and 60-85
      years) . The phase Ⅱ clinical trials designed 8 research group, including two immunization
      procedures (0, 21 days and 0, 14, 28 days), two doses (20μg/0.5ml, 40μg/1.0ml) and two ages
      group (adults and elder): Each group including 120 participants. Vaccination or placebo group
      will be randomly assigned to receive in a 5:1 ratio, 960 in total.
    
  